DLL3 and small cell lung carcinoma: Consequently, researchers have developed an antibody as a real-time, noninvasive, and quantitative approach to facilitate the selection of patients for Rova-T treatment based on in vivo DLL3 expression status using PET imaging in a preclinical mouse model of SCLC [7].